home / stock / knsa / knsa news


KNSA News and Press, Kiniksa Pharmaceuticals Ltd. From 05/07/24

Stock Information

Company Name: Kiniksa Pharmaceuticals Ltd.
Stock Symbol: KNSA
Market: NASDAQ

Menu

KNSA KNSA Quote KNSA Short KNSA News KNSA Articles KNSA Message Board
Get KNSA Alerts

News, Short Squeeze, Breakout and More Instantly...

KNSA - Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. East...

KNSA - Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

2024-04-24 13:34:34 ET Summary Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. Kiniksa plans to ...

KNSA - Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript

2024-04-23 13:59:07 ET Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice Preside...

KNSA - Kiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlook

2024-04-23 07:37:59 ET More on Kiniksa Pharmaceuticals Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial information for Kiniksa Pharmaceuticals Read the full article on Seeking Alp...

KNSA - Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abiprubart Phase 2b trial in Sjög...

KNSA - Expected US Company Earnings on Tuesday, April 23rd, 2024

Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...

KNSA - Kiniksa Pharmaceuticals Q1 2024 Earnings Preview

2024-04-22 17:05:04 ET More on Kiniksa Pharmaceuticals Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial informati...

KNSA - Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio ...

KNSA - Where are the Opportunities in (KNSA)

2024-04-02 22:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

KNSA - (KNSA) Investment Analysis and Advice

2024-03-23 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Previous 10 Next 10